Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Aldosterone Synthase Inhibitors
Author(s): Shubh K Patel , Hwee Teoh , Ahreni Saunthar , et al Added: 8 months ago

Cardiovascular Kidney Metabolic

Heart Failure
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 1 year ago

Heart Failure
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 9 months ago

Heart Failure
Management of Hyperkalaemia in Patients with Cardiorenal Disease
Author(s): Antonio Méndez-Durán , Juan B Ivey-Miranda , Genaro H Mendoza-Zavala , et al Added: 1 week ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
Author(s): Javed Butler , Dinesh Khullar , John JV McMurray , et al Added: 5 months ago
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He… View more

Prevention & Chronic Conditions

Heart Failure
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
The Aldosterone Story: New Chapters
Author(s): Vijay Chopra Added: 9 months ago

Heart Failure
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Added: 8 months ago Source:  Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac… View more

Guidelines & Statements

Heart Failure
Emerging Strategies in Aldosterone Inhibition: A Special Focus
Author(s): Vijay Chopra Added: 11 months ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps… View more

Heart Failure